Anavex Life Sciences Says First Patients With Rett Syndrome From The ANAVEX2-73-RS-003 Study Could Continue Treatment With ANAVEX2-73 (Blarcamesine) As Health Canada Approves Special Access Program
Portfolio Pulse from Benzinga Newsdesk
Anavex Life Sciences announced that the first patients with Rett Syndrome from the ANAVEX2-73-RS-003 study can continue treatment with ANAVEX2-73 (blarcamesine) as Health Canada approves the Special Access Program, allowing compassionate use of the drug after the 48-week open-label extension study.
June 15, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anavex Life Sciences' ANAVEX2-73 (blarcamesine) receives Health Canada approval for Special Access Program, allowing Rett Syndrome patients to continue treatment.
The approval of the Special Access Program by Health Canada for ANAVEX2-73 (blarcamesine) is a positive development for Anavex Life Sciences. This allows the company to continue providing treatment to Rett Syndrome patients, potentially leading to increased demand for the drug and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100